Natco Pharma's Kothur unit classified as 'voluntary action indicated' by US regulator

Natco Pharma Ltd announced that its Kothur unit in Hyderabad received an Establishment Inspection Report (EIR) from the US FDA, classifying the facility as 'Voluntary Action Indicated' (VAI). The US FDA had previously conducted an inspection of the company's pharma division at the Kothur location. While objectionable conditions were noted, the agency does not plan immediate regulatory action.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8N9RW41
via IFTTT